Are EHRs and Physicians Out of Sync?
In the past decade, the U.S. health-care system has undergone a historic transformation from a paper-based system to electronic health records (EHRs), which – thanks to government mandates – have reached nearly 100 percent...
Online Exclusives
Primary Care Physicians Face Tight Competition
Long hours and low pay make family practice an unappealing option for many aspiring physicians. According to a report from the Health Care Cost...
Next Generation Sequencing Tests to Receive Less Scrutiny
The U.S. Food and Drug Administration (FDA) will change its regulatory approach to next generation sequencing (NGS) tests, re-classifying them as moderate-risk medical devices....
News
From the Blood Journals
Brentuximab Vedotin and CHP Combination Leads to Lasting Remissions in Peripheral...
Half of patients with peripheral T-cell lymphomas (PTCLs) who were treated with brentuximab vedotin in combination with CHP (cyclophosphamide, doxorubicin, prednisone) remained in remission...
The Effect of Moxetumomab Pasudotox on Minimal Residual Disease in Hairy...
Nearly two-thirds of patients with relapsed/refractory hairy cell leukemia (HCL) who were treated with the anti-CD22 recombinant immunotoxin moxetumomab pasudotox achieved complete remission (CR),...
Multimedia
Pulling Back the Curtain: Olatoyosi Odenike, MD
Hear more from our interview with Dr. Odenike, where she describes finding her home in hematology, and offers advice for early-career doctors.
Big Questions, Tough Answers: Norman “Ned” Sharpless, MD
In more from our interview, Dr. Sharpless shares his vision as National Cancer Institute Director and for overcoming the obstacles to advancing research.
Pulling Back the Curtain: Andra James, MD, MPH
Hear more from our interview with Dr. James, where she shares more about the patients who inspired her to pursue hematology and the importance...
Luc-Matthieu Fornecker, MD, PhD: Risks and Benefits of BV + AVD...
In the multicenter BREACH trial, adding brentuximab vedotin to AVD chemotherapy in patients with unfavorable, early-stage Hodgkin lymphoma led to higher rates of PET...
On Location
A Curative Strategy for High-Risk Smoldering Multiple Myeloma?
In a phase II trial of patients with previously untreated smoldering multiple myeloma (SMM), the...
Final Analysis of IFM2009 Trial Confirms Predictive Value of Minimal Residual Disease in Myeloma
Because survival for patients with multiple myeloma (MM) has significantly improved within the past decade,...
Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma
According to final results from the phase III ASPIRE study assessing patients with relapsed/refractory multiple...
Doubling Down on Double Transplant for Myeloma: Updated Results from EMN02/H095
More than a year ago, at the 2016 ASH Annual Meeting, Michele Cavo, MD, from...
BCMA Antibody Drug Conjugate Active in Patients With Heavily Pretreated Myeloma
In a phase I study presented at the 2017 ASH Annual Meeting, 60 percent of...
Early-Phase Study Finds Venetoclax Plus Obinutuzumab Safe and Effective in Patients with Untreated CLL
Venetoclax – a highly selective, potent BCL2 inhibitor – demonstrated significant anti-tumor activity in patients...
Latest Headlines
ASH Directions
Roundtable Discussion With Senator Booker, The Hematologist App Now Available, and more
ASH Participates in Roundtable Discussion With Senator Booker
On February 28, Sens. Tim Scott (R-SC) and Cory Booker (D-NJ) introduced the Sickle Cell Disease...
MEI Develops Future Leaders, 2018 ASH-AMFDP Scholars Selected, and more
ASH Medical Educators Institute Develops Future Leaders
The American Society of Hematology (ASH) Medical Educators Institute (MEI) develops future leaders in hematology education through...
Remembering Ihor R. Lemischka and Günter Blobel, Feinstein Institute Researcher Awarded NIH Grant, and...
Remembering Ihor R. Lemischka (1953-2017)
Ihor R. Lemischka, PhD, a pioneer in the fields of hematopoiesis and pluripotent cell biology, died on December 17, 2017.Dr....
Mohamad Cherry Joins Atlantic Health System, Remembering Eliezer A. Rachmilewitz, and more
Remembering Eliezer A. Rachmilewitz, MD
Eliezer A. Rachmilewitz, MD, professor emeritus of medicine at the Hebrew University Hadassah Medical School in Jerusalem, died on December...
Amelia Langston Named Medical Director of Winship Cancer Network, Jordan Scott Orange Receives Edith...
Amelia Langston Named Medical Director of Winship Cancer Network
Amelia (Amy) Langston, MD, joined the Winship Cancer Institute of Emory University as medical director of...
Are EHRs and Physicians Out of Sync?
In the past decade, the U.S. health-care system has undergone a historic transformation from a paper-based system to electronic health records (EHRs), which –...
Contract Research Organizations: Outsourced Trials, Outsized Problems
A ranking of sorts is sent out every week to the chosen ones, but those who find themselves in the top spots don’t feel...
Controversies in Myeloma: The Who, When, and Why of Treatment
The recent expansion of treatment options for patients with multiple myeloma (MM) has introduced new opportunities for redefining the goals of therapy. At the...
